Phase II Trial Of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 May 2016
At a glance
- Drugs Capmatinib (Primary) ; Ceritinib (Primary) ; Entrectinib (Primary) ; Regorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 May 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 12 May 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
- 12 May 2016 Status changed from not yet recruiting to active, no longer recruiting.